PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis

NASDAQ:PRTA • IE00B91XRN20

8.97 USD
-0.1 (-1.1%)
At close: Feb 24, 2026
8.97 USD
0 (0%)
After Hours: 2/24/2026, 4:30:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to PRTA. PRTA was compared to 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. PRTA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PRTA has reported negative net income.
  • PRTA had a negative operating cash flow in the past year.
  • In the past 5 years PRTA reported 4 times negative net income.
  • PRTA had negative operating cash flow in 4 of the past 5 years.
PRTA Yearly Net Income VS EBIT VS OCF VS FCFPRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • PRTA has a Return On Assets of -79.53%. This is in the lower half of the industry: PRTA underperforms 66.99% of its industry peers.
  • PRTA has a Return On Equity (-95.07%) which is in line with its industry peers.
Industry RankSector Rank
ROA -79.53%
ROE -95.07%
ROIC N/A
ROA(3y)-39.39%
ROA(5y)-24.52%
ROE(3y)-46.11%
ROE(5y)-28.55%
ROIC(3y)N/A
ROIC(5y)N/A
PRTA Yearly ROA, ROE, ROICPRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • PRTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTA Yearly Profit, Operating, Gross MarginsPRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRTA remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for PRTA has been increased compared to 5 years ago.
  • PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRTA Yearly Shares OutstandingPRTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PRTA Yearly Total Debt VS Total AssetsPRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -1.24, we must say that PRTA is in the distress zone and has some risk of bankruptcy.
  • PRTA has a Altman-Z score (-1.24) which is comparable to the rest of the industry.
  • PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.24
ROIC/WACCN/A
WACC7.7%
PRTA Yearly LT Debt VS Equity VS FCFPRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.61 indicates that PRTA has no problem at all paying its short term obligations.
  • PRTA has a Current ratio of 6.61. This is in the better half of the industry: PRTA outperforms 67.18% of its industry peers.
  • PRTA has a Quick Ratio of 6.61. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of PRTA (6.61) is better than 67.95% of its industry peers.
Industry RankSector Rank
Current Ratio 6.61
Quick Ratio 6.61
PRTA Yearly Current Assets VS Current LiabilitesPRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • PRTA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.87%.
  • Looking at the last year, PRTA shows a very negative growth in Revenue. The Revenue has decreased by -92.83% in the last year.
  • Measured over the past years, PRTA shows a very strong growth in Revenue. The Revenue has been growing by 60.83% on average per year.
EPS 1Y (TTM)-70.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.96%
Revenue 1Y (TTM)-92.83%
Revenue growth 3Y-43.57%
Revenue growth 5Y60.83%
Sales Q2Q%-99.01%

3.2 Future

  • PRTA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.02% yearly.
  • PRTA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 88.83% yearly.
EPS Next Y115.46%
EPS Next 2Y33.17%
EPS Next 3Y25.53%
EPS Next 5Y22.02%
Revenue Next Year1183.79%
Revenue Next 2Y73.59%
Revenue Next 3Y109.06%
Revenue Next 5Y88.83%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PRTA Yearly Revenue VS EstimatesPRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
PRTA Yearly EPS VS EstimatesPRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 14.76 indicates a correct valuation of PRTA.
  • 96.16% of the companies in the same industry are more expensive than PRTA, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 28.01. PRTA is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 14.76
PRTA Price Earnings VS Forward Price EarningsPRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTA Per share dataPRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PRTA's earnings are expected to grow with 25.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.17%
EPS Next 3Y25.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PRTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROTHENA CORP PLC

NASDAQ:PRTA (2/24/2026, 4:30:00 PM)

After market: 8.97 0 (0%)

8.97

-0.1 (-1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)05-06
Inst Owners79.92%
Inst Owner Change9.12%
Ins Owners19.38%
Ins Owner Change0%
Market Cap482.86M
Revenue(TTM)9.68M
Net Income(TTM)-280.46M
Analysts75.38
Price Target20.74 (131.22%)
Short Float %16.28%
Short Ratio11.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.94%
Min EPS beat(2)-28.86%
Max EPS beat(2)2.98%
EPS beat(4)1
Avg EPS beat(4)-10.08%
Min EPS beat(4)-28.86%
Max EPS beat(4)2.98%
EPS beat(8)3
Avg EPS beat(8)21.35%
EPS beat(12)6
Avg EPS beat(12)43.16%
EPS beat(16)6
Avg EPS beat(16)21.31%
Revenue beat(2)0
Avg Revenue beat(2)-41.76%
Min Revenue beat(2)-64.33%
Max Revenue beat(2)-19.2%
Revenue beat(4)0
Avg Revenue beat(4)-52.91%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-19.2%
Revenue beat(8)1
Avg Revenue beat(8)86.12%
Revenue beat(12)3
Avg Revenue beat(12)64.36%
Revenue beat(16)3
Avg Revenue beat(16)25.69%
PT rev (1m)0%
PT rev (3m)23.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-79.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-46.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.76
P/S 40.97
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-3.93
EYN/A
EPS(NY)0.61
Fwd EY6.77%
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS0.22
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.53%
ROE -95.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.39%
ROA(5y)-24.52%
ROE(3y)-46.11%
ROE(5y)-28.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.16%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.61
Quick Ratio 6.61
Altman-Z -1.24
F-Score3
WACC7.7%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.96%
EPS Next Y115.46%
EPS Next 2Y33.17%
EPS Next 3Y25.53%
EPS Next 5Y22.02%
Revenue 1Y (TTM)-92.83%
Revenue growth 3Y-43.57%
Revenue growth 5Y60.83%
Sales Q2Q%-99.01%
Revenue Next Year1183.79%
Revenue Next 2Y73.59%
Revenue Next 3Y109.06%
Revenue Next 5Y88.83%
EBIT growth 1Y-32.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.67%
OCF growth 3YN/A
OCF growth 5YN/A

PROTHENA CORP PLC / PRTA FAQ

What is the ChartMill fundamental rating of PROTHENA CORP PLC (PRTA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PRTA.


What is the valuation status for PRTA stock?

ChartMill assigns a valuation rating of 3 / 10 to PROTHENA CORP PLC (PRTA). This can be considered as Overvalued.


What is the profitability of PRTA stock?

PROTHENA CORP PLC (PRTA) has a profitability rating of 0 / 10.